Tourmaline Bio Financials
This page shows Tourmaline Bio (TRML) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Tourmaline Bio does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Tourmaline Bio passes 0 of 6 computable financial strength tests (3 of the nine could not be computed from available data). No profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Tourmaline Bio reported a net loss of $73.2M while operations used $77.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Tourmaline Bio's EBITDA was -$89.7M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 97.7% from the prior year.
Tourmaline Bio reported -$73.2M in net income in fiscal year 2024. This represents a decrease of 73.8% from the prior year.
Not reported for fiscal year 2024.
Cash & Balance Sheet
Tourmaline Bio recorded an outflow of $77.3M in free cash flow in fiscal year 2024, representing a cash shortfall after capex. This represents a decrease of 174.6% from the prior year.
Tourmaline Bio held $30.5M in cash as of fiscal year 2024; long-term debt is not reported for that period.
Not reported for fiscal year 2024.
Margins & Returns
Tourmaline Bio's ROE was -24.4% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is down 3.9 percentage points from the prior year.
Not reported for fiscal year 2024.
Not reported for fiscal year 2024.
Not reported for fiscal year 2024.
Capital Allocation
Tourmaline Bio invested $67.0M in research and development in fiscal year 2024. This represents an increase of 106.9% from the prior year.
Tourmaline Bio spent $4K on share buybacks in fiscal year 2024, returning capital to shareholders by reducing shares outstanding.
Tourmaline Bio invested $9K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 83.9% from the prior year.
TRML Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|
| R&D Expenses | N/A | $67.0M+106.9% | $32.4M+84.7% | $17.5M-48.8% | $34.2M+124.1% | $15.3M |
| SG&A Expenses | N/A | $22.7M+74.4% | $13.0M+499.6% | $2.2M-83.6% | $13.3M+79.1% | $7.4M |
| Operating Income | N/A | -$89.7M-97.6% | -$45.4M-130.5% | -$19.7M+58.5% | -$47.5M-109.4% | -$22.7M |
| Interest Expense | N/A | $0 | $0 | N/A | N/A | N/A |
| Income Tax | N/A | $0 | $0 | $0 | $0 | $0 |
| Net Income | N/A | -$73.2M-73.8% | -$42.1M-113.8% | -$19.7M+58.8% | -$47.8M-110.7% | -$22.7M |
| EPS (Diluted) | — | -$2.89 | -$8.87 | -$22.46 | -$1.64 | N/A |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit.
TTM is the trailing twelve months, Q3 FY2024 through Q2 FY2025, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
TRML Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|
| Total Assets | $309.0M+46.9% | $210.3M+2211.4% | $9.1M-96.4% | $251.4M+64.6% | $152.8M |
| Current Assets | $268.8M+28.7% | $208.9M+2412.9% | $8.3M-96.6% | $246.5M+63.5% | $150.8M |
| Cash & Equivalents | $30.5M-78.3% | $140.7M+1604.1% | $8.3M-55.6% | $18.6M+5.8% | $17.6M |
| Total Liabilities | $8.9M+70.4% | $5.3M-81.8% | $28.8M-88.5% | $251.6M+31.8% | $190.9M |
| Current Liabilities | $8.9M+78.1% | $5.0M+267.0% | $1.4M-82.9% | $8.0M+134.6% | $3.4M |
| Total Equity | $300.1M+46.3% | $205.0M+1139.1% | -$19.7M-8631.0% | -$226K+99.4% | -$38.1M |
| Retained Earnings | -$135.3M-118.0% | -$62.1M-211.4% | -$19.9M+78.1% | -$90.8M-111.2% | -$43.0M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
TRML Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -$86.3M | -$77.3M-175.1% | -$28.1M-334.8% | -$6.5M+83.9% | -$40.0M-108.1% | -$19.2M |
| Capital Expenditures | $25K | $9K-83.9% | $56K-17.6% | $68K-97.2% | $2.4M+89.5% | $1.3M |
| Free Cash Flow | -$86.3M | -$77.3M-174.6% | -$28.1M-331.2% | -$6.5M+84.6% | -$42.4M-107.0% | -$20.5M |
| Investing Cash Flow | $46.9M | -$194.3M-5160.0% | $3.8M+175.8% | -$5.1M+94.7% | -$96.4M+27.7% | -$133.3M |
| Financing Cash Flow | $612K | $161.3M+3.0% | $156.7M+689.5% | $19.9M-85.6% | $137.4M+4.8% | $131.1M |
| Share Buybacks | $11K | $4K | $0 | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Dividends Paid.
TTM is the trailing twelve months, Q3 FY2024 through Q2 FY2025, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
TRML Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|
| Return on Equity | -24.4%-3.9pp | -20.5% | N/A | N/A | N/A |
| Return on Assets | -23.7%-3.7pp | -20.0%+196.5pp | -216.5%-197.5pp | -19.0%-4.2pp | -14.9% |
| Current Ratio | 30.18-11.6x | 41.76+35.7x | 6.10-24.8x | 30.86-13.4x | 44.29 |
| Debt-to-Equity | 0.030.0x | 0.03 | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Tourmaline Bio Ranks
Frequently Asked Questions
Is Tourmaline Bio profitable?
No, Tourmaline Bio (TRML) reported a net income of -$73.2M in fiscal year 2024.
What is Tourmaline Bio's EBITDA?
Tourmaline Bio (TRML) had EBITDA of -$89.7M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Tourmaline Bio's return on equity (ROE)?
Tourmaline Bio (TRML) has a return on equity of -24.4% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.
What is Tourmaline Bio's free cash flow?
Tourmaline Bio (TRML) recorded an outflow of $77.3M in free cash flow during fiscal year 2024. This represents a -174.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Tourmaline Bio's operating cash flow?
Tourmaline Bio (TRML) recorded an outflow of $77.3M in operating cash flow during fiscal year 2024, representing cash used by core business activities.
What are Tourmaline Bio's total assets?
Tourmaline Bio (TRML) had $309.0M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Tourmaline Bio's capital expenditures?
Tourmaline Bio (TRML) invested $9K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Tourmaline Bio spend on research and development?
Tourmaline Bio (TRML) invested $67.0M in research and development during fiscal year 2024.
What is Tourmaline Bio's current ratio?
Tourmaline Bio (TRML) had a current ratio of 30.18 as of fiscal year 2024, which is generally considered healthy.
What is Tourmaline Bio's debt-to-equity ratio?
Tourmaline Bio (TRML) had a debt-to-equity ratio of 0.03 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Tourmaline Bio's return on assets (ROA)?
Tourmaline Bio (TRML) had a return on assets of -23.7% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Tourmaline Bio's cash runway?
Based on fiscal year 2024 data, Tourmaline Bio (TRML) had $30.5M in cash against an annual operating cash burn of $77.3M. This gives an estimated cash runway of approximately 5 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Tourmaline Bio's Piotroski F-Score?
Tourmaline Bio (TRML) has a Piotroski F-Score of 0 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Tourmaline Bio's earnings high quality?
Tourmaline Bio (TRML) reported a net loss of $73.2M while operations used $77.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.